Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?

Sponsor
Seoul National University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05945511
Collaborator
(none)
2,295
1
8.8
261.6

Study Details

Study Description

Brief Summary

Treatment and follow-up strategies for silent gallbladder (GB) stones in patients before KT (Kidney transplantation) remain unknown. Therefore, we aimed to assess the risk of gallstone-related biliary complications and post-cholecystectomy complications in KT recipients, to elucidate the role of prophylactic cholecystectomy in this population.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Kidney transplantation (KT) is the best treatment option for patients with end-stage kidney disease (ESKD) although donor deficit remains a main problem. Hence, the survival extension of both KT recipients and their invaluable grafts should be prioritized. A thorough pretransplant evaluation is essential in identifying and managing any risk factors associated with adverse outcomes for both patients and grafts following KT. Candidates typically undergo various types of intra-abdominal imaging before KT surgery to assess the anatomical structures of the renal vasculature and urinary tract, which is crucial for detailed surgery planning and to rule out any pre-existing malignancies or concealed infectious complications. Asymptomatic gallstones may be incidentally discovered during the evaluation, but optimal management and follow-up strategies for these gallstones in KT candidates remain unclear.

    Asymptomatic gallstone management in the general population is typically based on the risk of developing relevant symptoms or complications. Previous large cohort studies have revealed that individuals with asymptomatic gallstones have a lifetime risk of approximately 7%-26% of developing serious symptoms or gallstone-related complications such as acute cholecystitis, acute cholangitis, and acute pancreatitis. The aftereffects should not be ignored even if cholecystectomy is performed in patients with asymptomatic gallstones. The incidence of complications after cholecystectomy in the general population is approximately 2.4%-9.4%, and the mortality rate is <1%. Therefore, prophylactic cholecystectomy is not usually recommended in the general population with asymptomatic gallstones.

    On the contrary, patients who underwent solid organ transplantation, including KT, had higher rates of both asymptomatic gallstones and postoperative complications after cholecystectomy than the general population. Several studies have revealed that 18%-39% of KT recipients with asymptomatic gallstones develop gallstone-related complications requiring surgery. The postoperative complication rate was approximately 15% and the mortality rate was up to 7% when subsequent cholecystectomy was performed, which indicates an increased morbidity, especially in the case of open surgery. Considering both, the benefit of prophylactic cholecystectomy in KT recipients is difficult to define. Several studies recommend prophylactic cholecystectomy for patients with asymptomatic gallstones who underwent solid organ transplants or those who will require immunosuppressants. Routine cholecystectomy is not typically performed by most transplant centers, despite these recommendations, even when silent gallstones are discovered during the pretransplant evaluation.

    Therefore, this retrospective cohort analysis aimed to assess the risk of gallstone-related biliary complications and post-cholecystectomy complications in KT recipients, to elucidate the role of prophylactic cholecystectomy in this population.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    2295 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
    Actual Study Start Date :
    Sep 7, 2022
    Actual Primary Completion Date :
    Mar 1, 2023
    Actual Study Completion Date :
    Jun 1, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    Kidney transplant patients

    KT recipients at Seoul national university hospital from January 2005 to July 2022.

    Outcome Measures

    Primary Outcome Measures

    1. biliary complications [through study completion, an average of 6 year]

      Incidence rate of biliary complication

    2. post-cholecystectomy complications [Within 1month after cholecystectomy]

      Incidence rate of post-cholecystectomy complication

    Secondary Outcome Measures

    1. Graft failure (GF) [After KT to study completion, an average of 6 year]

      Incidence rate of graft failure after kidney transplantation

    2. Death-censored graft failure (DCGF) [After KT to study completion, an average of 6 year]

      Incidence rate of Death-censored graft failure after kidney transplantation

    3. All-cause mortality [through study completion, an average of 6 year]

      Incidence rate of death

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Kidney transplantation patients
    Exclusion Criteria:
    1. patients aged <18 years

    2. patients followed for <3 months

    3. patients without evidence of gallstones on abdominal imaging studies

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Seoul National University Hospital Seoul Korea, Republic of 03080

    Sponsors and Collaborators

    • Seoul National University Hospital

    Investigators

    • Principal Investigator: Myeong Hwan Lee, M.D, Seoul National University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Woo Hyun Paik, Professor, Seoul National University Hospital
    ClinicalTrials.gov Identifier:
    NCT05945511
    Other Study ID Numbers:
    • 2209-029-1355
    First Posted:
    Jul 14, 2023
    Last Update Posted:
    Jul 14, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 14, 2023